ArticleFrontiers in immunology2026

Influence of immune checkpoint inhibitor target and timing on combination treatment with antibody-based β-emitting targeted radionuclide therapy across tumor immunogenicity profiles.

Simone C Kleinendorst et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.